Loading
In 174 Indian gallbladder cancers, about a quarter had PD-L1 on tumour cells and a quarter on immune cells, more so in higher-grade tumours, but PD-L1 did not predict survival.
174 cases of gallbladder carcinoma were evaluated for PD-L1 expression with the SP263 clone on tissue microarrays, at cut-offs of 1%, 10% and 50% in tumour cells and in tumour-infiltrating lymphocytes, and correlated with clinicopathological characteristics and survival. Mean age was 49.9 years, the male to female ratio 1 to 2.9, and 73.6% presented with stage 3 or 4 disease.
Tumour cells expressed PD-L1 in 23.0% of cases and tumour-infiltrating lymphocytes in 24.1%; at cut-offs of 10% and 50%, 14.9% and 7.5% of cases were positive. Tumour proportion score was associated with histological type, histological and nuclear grade, nodal metastasis, higher stage and tumour-infiltrating lymphocytes. Paired lymph node metastases showed discordantly higher PD-L1 than primaries. Overall survival was not associated with PD-L1 expression (P = 0.546).
The largest PD-L1 series from a high-incidence country; the one-in-four figure is the number quoted for gallbladder cancer, though the Western series with a different clone found fewer. No biliary approval uses PD-L1 to select patients.
Shares PD-L1 TPS (tumour proportion score), Tumour-infiltrating lymphocytes (TILs), Immunohistochemistry (IHC), PD-L1.
Shares PD-L1 TPS (tumour proportion score), Tumour-infiltrating lymphocytes (TILs), Immunohistochemistry (IHC), PD-L1.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-L1.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-L1.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-L1.
Shares Tumour-infiltrating lymphocytes (TILs), Gallbladder cancer.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-L1.